浙江寿仙谷医药股份有限公司 2023 年半年度募集资金存放与实际使用情况的专项报告 | 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2023-52 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据中国证券监督管理委员会（以下简称"中国证监会"）《上市公司监管指 引第 2 号——上市公司募集资金管理和使用的监管要求》、《上海证券交易所上市 公司自律监管指引第 1 号——规范运作》以及《上海证券交易所上市公司自律监 管指南第 1 号——公告格式》等有关规定，现将浙江寿仙谷医药股份有限公司 （以下简称"公司"或"寿仙谷"）2023 年半年度募集资金存放与使用情况专项说明 如下： 一、募集资金基本情况 （一）2020 年公开发行可转换公司债券募集资金 1、实际募集资金金额和资金到账时间 经中国证监会《关于核准浙江寿仙谷医药股份有限公司公开发行可转换公司 债券的批复》（证监许可[2020] ...

浙江中远资产评估有限公司 ZHEJIANG ZHONGYUAN ASSEST APPRAISAL CO.,LTD. ZHONG YUAN PTF 杭州运河集团建设管理有限公司拟转让股权及债权 涉及的杭州运河恒立商业地产有限公司 股权及债权市场价值评估项目 资产评估报告 本资产评估报告依据中国资产评估准则编制 杭州运河集团建设管理有限公司拟转让股权及债权 涉及的杭州运河恒立商业地产有限公司 股权及债权市场价值评估项目 资产评估报告 浙中远评〔 2023 〕032 号 浙江中远资产评估有限公司 二〇二三年六月四日 | . | | --- | | 资产深化师声明,… | | --- | | 资产评估报告。摘要… | | 资产评估报告 · 正文 | | 一、委托人及其他评估报告使用人 | | 一、评估目的 | | 三、逐估对象和评估范围 | | 。 价值类型 …………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… 10 | | 五、评估其准日 | | 六、汪仕依据… ...

上会浙报字(2023) 399 号 杭州运河恒立商业地产有限公司 清产核资的专项审计报告 上会浙报字(2023)第399号 上会会计师事务所(特殊普通合伙)浙江分所 中国杭州 | 一、清产核资工作范围及概况… | | --- | | 二、清产核资专项审计的依据… | | 三、清产核资过程及实施情况… | | 四、清产核资专项审计情况 | | 五、主要会计政策、会计估计及重要报表项目说明 … | | 六、重大事项专项说明 . | | 七、公司关联方及交易 | | 八、本报告适用范围 ………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… 12 | 录 目 令计师事务所（特殊普通合伙） ghai Centified Public Accountants (Special General Partnersh 杭州运河恒立商业地产有限公司 清产核资的专项审计报告 k. - 4 4 杭州运河集团建设管理有限公司: 我们接受委托,对杭州运河恒立商业地产有限公司（以下或简称"恒立公司" ...

浙江寿仙谷医药股份有限公司 关于竞得杭州运河恒立商业地产有限公司 | 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2023-049 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | | 100%股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次交易不构成重大资产重组 本次交易事项已经公司第四届董事会第十四次会议审议通过 本次交易符合公司的发展战略规划布局，同时进行了充分的分析，但仍 然存在经营阶段遇到市场不稳定和经营管理风险的可能性，以及资源整合未达到 预期效果的可能性，敬请广大投资者注意投资风险。 一、交易概述 （一）基本情况 近日，浙江寿仙谷医药股份有限公司（以下简称"公司"或"本公司"）参 与竞购杭州运河集团建设管理有限公司（以下简称"运河建管公司"）在杭州产权 交易所有限责任公司（以下简称"杭交所"）公开挂牌转让的杭州运河恒立商业地 产有限公司（以下简称"恒立公司"）100%股权事项，并于 2023 ...

| 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2023-018 | | --- | --- | --- | --- | | 债券代码：113585 | 债券简称：寿仙转债 | | | | 债券代码：113660 | 债券简称：寿 | 22 转债 | | 浙江寿仙谷医药股份有限公司 关于参加沪市主板生物医药行业上市公司 2022 年年报 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 浙江寿仙谷医药股份有限公司（以下简称"公司"）于 2023 年 04 月 19 日发 布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经 营成果、财务状况，同时更加充分地向投资者展示生物医药行业发展情况，公司计 划于 2023 年 05 月 12 日下午 15:00-16:30 参加沪市主板生物医药行业上市公司 2022 年年报集体业绩说明会，就投资者关心的问题进行交流。 二、说明会召开的时间、地点及活动日程 （一）会议召开时间：2023 年 05 月 1 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 206,156,004.83, representing a year-on-year increase of 1.20%[4] - The net profit attributable to shareholders for Q1 2023 was CNY 62,610,490.08, reflecting a growth of 6.13% compared to the same period last year[4] - The basic earnings per share for Q1 2023 was CNY 0.32, which is an increase of 6.67% year-on-year[5] - Total operating revenue for Q1 2023 was CNY 206,156,004.83, a slight increase of 0.21% compared to CNY 203,720,149.88 in Q1 2022[19] - Net profit for Q1 2023 reached CNY 62,610,490.08, representing an increase of 2.47% from CNY 59,142,082.00 in Q1 2022[20] - Earnings per share for Q1 2023 were CNY 0.32, compared to CNY 0.30 in Q1 2022, reflecting a growth of 6.67%[20] - Other comprehensive income after tax for Q1 2023 was CNY 5,723,141.98, compared to CNY 4,875,301.97 in Q1 2022, indicating a growth of 17.38%[20] Assets and Liabilities - The total assets at the end of Q1 2023 amounted to CNY 2,984,851,552.15, up 4.50% from the end of the previous year[5] - As of March 31, 2023, the total assets of Zhejiang Shuxian Valley Pharmaceutical Co., Ltd. amounted to CNY 2,984,851,552.15, an increase from CNY 2,856,189,559.66 at the end of 2022, reflecting a growth of approximately 4.5%[14] - The company's cash and cash equivalents reached CNY 1,624,310,541.31, up from CNY 1,524,712,390.54 at the end of 2022, indicating an increase of about 6.5%[14] - Inventory levels increased to CNY 164,854,744.62 from CNY 147,756,333.74, representing a rise of approximately 11.6%[14] - The total liabilities of the company increased to CNY 951,224,146.27 from CNY 890,354,337.34, reflecting a growth of about 6.8%[15] - Total liabilities as of Q1 2023 were CNY 1,010,947,011.71, an increase of 6.34% from CNY 950,667,244.96 in Q1 2022[19] Cash Flow - The net cash flow from operating activities for Q1 2023 was CNY 78,770,447.68, showing a decrease of 3.13% compared to the previous year[4] - Cash flow from operating activities for Q1 2023 was CNY 78,770,447.68, a decrease of 3.09% from CNY 81,311,500.62 in Q1 2022[21] - Cash inflow from operating activities totaled CNY 242,844,419.45 in Q1 2023, an increase of 8.14% from CNY 224,529,100.62 in Q1 2022[21] - In Q1 2023, the net cash flow from investing activities was -$48,674,579.89, compared to -$47,430,058.40 in the previous year[23] - The total cash inflow from financing activities was $302,925,760.00, with cash outflow totaling $308,423,477.02, resulting in a net cash flow of -$5,497,717.02[23] - The cash generated from financing activities included $187,925,760.00 from borrowings and $115,000,000.00 from other financing activities[23] - The net increase in cash and cash equivalents for Q1 2023 was $24,598,150.77, compared to $27,686,518.37 in the previous year[23] Shareholder Information - The company reported a total of 15,244 common shareholders at the end of the reporting period[10] - The top shareholder, Zhejiang Shouxian Valley Investment Management Co., Ltd., holds 28.76% of the shares, amounting to 56,711,239 shares[10] Other Financial Metrics - The weighted average return on equity for Q1 2023 was 3.23%, a decrease of 0.34 percentage points year-on-year[5] - The total current liabilities increased to CNY 531,550,902.54 from CNY 477,765,151.63, reflecting a growth of about 11.2%[15] - The company's long-term investments in equity increased slightly to CNY 5,988,270.17 from CNY 5,927,692.09, showing a growth of approximately 1.0%[14] - The non-current assets totaled CNY 1,015,937,901.80, up from CNY 994,178,202.27, indicating an increase of about 2.5%[15] - The company's accounts receivable decreased to CNY 88,648,652.43 from CNY 113,660,007.77, a decline of approximately 22.0%[14] - Research and development expenses for Q1 2023 were CNY 11,429,365.94, an increase of 5.68% from CNY 10,816,003.23 in Q1 2022[19] Prepayments - The company experienced a significant increase in prepayments, with a rise of 117.20% in advance payments received during the reporting period[8] - The company reported a significant increase in prepayments to CNY 15,193,252.07 from CNY 13,965,241.53, which is an increase of approximately 8.8%[14] Accounting Standards - The company did not apply new accounting standards or interpretations for the first time in 2023[25]

Financial Performance - The company's operating revenue for 2022 was approximately CNY 829.07 million, representing an increase of 8.07% compared to CNY 767.14 million in 2021[25]. - Net profit attributable to shareholders of the listed company reached approximately CNY 277.78 million, a significant increase of 38.32% from CNY 200.83 million in the previous year[25]. - The net profit after deducting non-recurring gains and losses was approximately CNY 253.18 million, up 27.39% from CNY 198.75 million in 2021[25]. - The company's total assets increased by 45.54% to approximately CNY 2.86 billion from CNY 1.96 billion in 2021[25]. - The weighted average return on net assets rose to 16.07%, an increase of 2.53 percentage points from 13.54% in the previous year[26]. - Basic earnings per share for 2022 were CNY 1.43, reflecting a 36.19% increase from CNY 1.05 in 2021[26]. - The cash flow from operating activities for 2022 was approximately CNY 341.28 million, an increase of 15.03% compared to CNY 296.70 million in 2021[25]. - The company's net assets attributable to shareholders reached approximately CNY 1.91 billion, up 17.65% from CNY 1.62 billion at the end of 2021[25]. Corporate Governance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants[5]. - All board members attended the board meeting, ensuring the integrity of the annual report[11]. - The company confirms that there are no non-operating fund occupations by controlling shareholders or related parties[8]. - The company has not violated any decision-making procedures in providing guarantees[9]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with relevant laws and regulations[190]. - The supervisory board is composed of 3 members, maintaining independence and oversight of the company's operations and management[190]. - The company strictly adheres to regulations regarding related party transactions, ensuring fairness and compliance in pricing and decision-making processes[191]. - There were no instances of non-operating fund occupation by the controlling shareholder or its affiliates during the reporting period[191]. Market Expansion and Strategy - The company plans to continue expanding its market presence and invest in new product development to drive future growth[24]. - The company signed contracts with 14 new city agents, expanding its sales network across multiple regions including Kunming, Guiyang, and Wuhan[36]. - The company launched a new marketing strategy that includes high-speed train advertisements, enhancing brand visibility across 18 provinces and regions[36]. - The company plans to expand its market presence outside Zhejiang province and increase efforts in community promotion and recruiting distributors for spore powder tablets[109]. - The company is focusing on the development of high-quality traditional Chinese medicine varieties, including Lingzhi and Dendrobium, supported by a clinical efficacy database[166]. - The company is actively pursuing key technology upgrades and digital transformation projects to enhance operational efficiency and product quality[175]. - The company aims to implement a development strategy centered on innovation in biotechnology and the cultivation of rare medicinal materials[165]. Research and Development - The company has a research and development team of 145 people, including 46 with senior titles and 11 PhDs[53]. - Research and development expenses amounted to 47.82 million yuan, a decrease of 5.90% from the previous year[98]. - The company is focusing on improving technology processes, developing new strains, and enhancing production equipment as part of its R&D strategy[138]. - The company has several ongoing R&D projects, including traditional Chinese medicine formulations aimed at various health conditions[140]. - The company is developing a new product, "寿仙谷牌铁皮石斛饮料," aimed at enhancing immunity, which is currently in the registration process[141]. - The company has maintained a consistent R&D investment strategy over the past three years, with a slight decrease in the percentage of revenue allocated to R&D[139]. - The company has registered multiple new health food products, including "Shouxiangu Brand Iron Skin Dendrobium Drink" and "Shouxiangu Brand Monkey Head Mushroom Dendrobium Huangqi Tablets"[146]. Product Development and Innovation - The company’s proprietary processing technology for Ganoderma lucidum has been patented in seven countries, showcasing its innovation in product development[38]. - The company’s new product lines, including "Xianhu 1," "Xianhu 2," and "Xianhu 3," have received national variety protection, indicating successful innovation in product offerings[38]. - The company has developed a rare medicinal plant germplasm resource bank, collecting 117 Dendrobium germplasm resources and achieving high survival rates and yields through modern breeding techniques[86]. - The company’s "Xianhua 1", "Xianhua 2", and "Xianhua 3" Ganoderma varieties have been recognized for their strong resistance and high active ingredient content, contributing to its competitive advantage[84]. - The company is actively working on the safety evaluation and pharmacological research of its traditional Chinese medicine products[140]. Social Responsibility and Community Engagement - The company is actively involved in social responsibility initiatives, including donations of health products to frontline medical workers[57]. - The company has implemented a "common prosperity model" that integrates rental income, labor, cooperative product sales, and technology promotion, which has received high praise from government bodies[57]. - The company has been awarded multiple honors, including being named a national science popularization education base and a green factory in Zhejiang Province[58]. Financial Management and Investments - The company’s investment activities generated a net cash flow of -85.39 million yuan, a significant improvement from -233.72 million yuan in the previous year[98]. - Cash and cash equivalents rose by 124.89% to ¥1,524,712,390.54, mainly due to funds received from the issuance of convertible bonds[128]. - The company’s bonds payable surged by 371.00% to ¥412,589,185.71, resulting from the issuance of convertible bonds during the reporting period[130]. - The company has proposed a plan for the public issuance of convertible bonds, with a feasibility analysis conducted on the use of raised funds[194]. Human Resources and Management - The total pre-tax remuneration for executives during the reporting period amounted to 452.55 million yuan[197]. - The company has implemented a "Four Eagles" human resources action plan to strengthen performance assessment and talent acquisition, focusing on attracting passionate and creative young talent[177]. - The management team has experienced changes, with several executives leaving and new appointments made to strengthen leadership[198]. - The leadership team includes professionals with extensive experience in finance, administration, and research, which is expected to drive innovation[200]. Future Outlook - Future guidance indicates a positive outlook for revenue growth and market expansion in the coming years[198]. - The company aims for a revenue growth rate and net profit growth rate of over 20% year-on-year in 2023[170]. - The company is committed to improving shareholder value through effective management and strategic initiatives[198].

2022 年第三季度报告 单位：元 币种：人民币 1 / 13 证券代码：603896 证券简称：寿仙谷 债券代码：113585 债券简称：寿仙转债 浙江寿仙谷医药股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | --- | |-----------------------------------------------|----------------|----------------------------------------|----------------|------ ...

Financial Performance - The company reported a half-year performance summary with no significant risks impacting operations[6]. - The company achieved a net profit attributable to shareholders of RMB 82.02 million, a year-on-year increase of 49.13%[22]. - The basic earnings per share increased to RMB 0.42, representing a growth of 44.83% compared to the same period last year[22]. - Operating revenue for the first half of the year was RMB 349.53 million, up 10.09% from RMB 317.49 million in the previous year[23]. - The net cash flow from operating activities reached RMB 184.90 million, reflecting a growth of 30.07% year-on-year[23]. - The company’s total assets increased by 4.31% to RMB 2.05 billion compared to the end of the previous year[23]. - The weighted average return on net assets rose to 4.96%, an increase of 1.00 percentage points from the previous year[22]. - The company reported a total revenue of 29,763.49 million RMB for the first half of 2022, with a gross margin of 86.31%[91]. - The company achieved an operating profit of ¥82,873,711.88, up from ¥56,397,609.83, reflecting a growth of 46.8% year-over-year[170]. - The company reported a total comprehensive income of ¥86,813,197.44 for the first half of 2022, compared to ¥58,252,348.06 in the same period of 2021, indicating a growth of 48.9%[171]. Corporate Governance - The board of directors confirmed the authenticity and completeness of the financial report[4]. - The report is unaudited, ensuring transparency in financial disclosures[4]. - The company has established an information management system to optimize market operations, resulting in improved profit margins[69]. - The company has committed to transparency and adherence to corporate governance standards in its operations[126]. - The company has maintained compliance with legal regulations regarding related party transactions and has ensured fair trading practices[126]. Risk Management - The management has outlined potential risks in the "Management Discussion and Analysis" section[6]. - The company emphasizes the importance of investor awareness regarding investment risks[5]. - The company faces risks related to natural disasters affecting the supply of key raw materials like Lingzhi and Dendrobium, which could impact production[98]. - The company has a risk of production qualification being revoked or not renewed, which could adversely affect operations[100]. Market Strategy and Expansion - The company plans to continue expanding its product line, focusing on high-quality traditional Chinese medicine and health products[28]. - The company maintains a strategy of optimizing its industrial layout and enhancing its core competitive advantages in the market[28]. - The company aims to leverage its advantages in seed sources and full industry chain to expand sales channels and establish "Shouxiangu" as a nationally recognized brand[47]. - The company plans to expand its market presence, focusing on the development of new products and technologies in the health sector[88]. - The company has established a "full industry chain" development model for products like Lingzhi and Dendrobium, ensuring standardized cultivation from breeding to processing[51]. Research and Development - The company has developed and certified three new Dendrobium varieties: "Xianhu 1," "Xianhu 2," and "Xianhu 3," which are characterized by high survival rates and strong resistance[57]. - The company has developed a patented "four lows and one high" ultrasonic low-temperature airflow breaking technology, significantly improving product safety and efficacy[62]. - The company has initiated several clinical trials related to its Ganoderma lucidum spore powder, including studies on its effects on immune function and its application in cancer treatment[72]. - The company received three new invention patents during the reporting period, enhancing its research and development capabilities[70]. Social Responsibility - The company actively donated products to frontline medical personnel during the COVID-19 pandemic, including donations to various hospitals and organizations[122]. - The "Shouxiangu Caring for Tumor Students" public welfare initiative has entered its fifth season, highlighting the company's commitment to social responsibility[122]. - The company has been recognized for its contributions to technological innovation and rural revitalization efforts by various provincial departments[121]. Shareholder Information - The company distributed a cash dividend of RMB 4.05 per 10 shares, totaling RMB 60.32 million, and increased its total share capital to 197.20 million shares[23]. - The company plans to issue convertible bonds, with a feasibility analysis report presented for shareholder approval[111]. - The total share capital after the distribution is 197,195,916 shares, reflecting an increase due to the capital reserve conversion[138]. - The company has no significant litigation or arbitration matters during the reporting period[129]. Financial Health - The company has maintained a strong debt repayment capability, having repaid all bank loans on time and in full without any overdue debts[159]. - The company’s credit rating remains stable at "AA-" for both the company and the convertible bonds, with no significant changes in creditworthiness[158]. - The total liabilities increased to ¥399,947,341.65 from ¥342,410,273.94, a growth of about 16.8%[164]. - The total owner's equity at the end of the current period reached approximately 1,647,038.7 million, reflecting growth in capital reserves[184].

2022 年第一季度报告 单位：元 币种：人民币 证券代码：603896 证券简称：寿仙谷 债券代码：113585 债券简称：寿仙转债 浙江寿仙谷医药股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人李明焱、主管会计工作负责人及会计机构负责人（会计主管人员）祝彪保证季度报告 中财务报表信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |-----------------------------------------------|----------------|---------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期增减 \n变动幅度 ( ...